A half-life is a measured property under specified conditions, not a number that can be read from a peptide's name. Claims that LR3 necessarily lasts a fixed number of hours in every person need an actual human pharmacokinetic source.
A rat study involving chronic renal failure examined clearance, degradation and binding of IGF-I analogues, including LR3. It showed that physiological context and binding behavior matter. It did not establish a universal duration for human use.
Ask which half-life was measured
A claim may refer to disappearance from blood, persistence in a tissue compartment, degradation in a sample or duration of a biological response. These are related but distinct questions. Replacing them all with “active for a day” hides important uncertainty.
Species, route, formulation and health status also need to remain attached to the measurement. An animal result cannot simply be copied into a human schedule, and a finding in a disease model cannot establish a value for everyone.
Reduced affinity for binding proteins does not settle the answer by itself. Binding can influence distribution and clearance as well as access to receptors. A plausible mechanism is a reason to investigate kinetics, not a substitute for measuring them.
The practical editorial test is straightforward: can the claimed number be traced to the same molecule, in humans, with a clearly described method and endpoint? If not, the article should label the uncertainty instead of repeating the number with increasing confidence.
This article gives no administration interval and does not suggest timing exposure around an assumed duration. The animal paper is included to explain why the question is more complicated than a name or marketing phrase.
A useful research summary can say what is known about the analogue while withholding an unsupported human clock. Precision sometimes means refusing to supply a number that the cited evidence cannot establish.